Search

Displaying results 621 - 630 of 10000 in total
  1. Drug

    Eribulin

    go.drugbank.com/drugs/DB08871
    ApprovedInvestigational

    Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].

    Products: ERIBULINA EG
  2. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract. … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]

    Mixtures: NuDroxiPAK N-500Products: Relafen DS
  3. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … [A32501] It is currently considered, in all the dosage forms, as a member of the list of approved inactive ingredients for drug products by the FDA.

    Categories: Compounds used in a research, industrial, or household settingProducts: Technescan DTPA Kit für ein radioaktives Arzneimittel, 20,8 mg
  4. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Synonyms: N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine, N,N-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamineProducts: Orphenadrine Citrate ER
  5. Drug

    Olanzapine

    go.drugbank.com/drugs/DB00334
    ApprovedInvestigational

    [A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548] … The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to

    Categories: Dopamine D2 Receptor AntagonistsProducts: MARATHON D, OLANZAPINA DR. REDDY'S
  6. Drug

    Betiatide

    go.drugbank.com/drugs/DB14082
    Approved

    Products: Renoscint MAG3 1 mg Kit für ein radioaktives Arzneimittel
  7. Drug

    Albuterol

    go.drugbank.com/drugs/DB01001
    ApprovedInvestigationalVet approved

    Salbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. … It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.

    Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, Combivent nebuliser solution in unit dose vialProducts: SALBUTAMOL JARABE DE 2 MG/5ML, SALBU EASYHALER0.1MG ED SK
  8. Drug

    Midodrine

    go.drugbank.com/drugs/DB00211
    ApprovedInvestigational

    An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.

    Synonyms: DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid, (±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamideProducts: MIDODRINA EG
  9. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    [A229083] Flupentixol is an antagonist of both D1 and D2 dopamine receptors. … Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms.

    Categories: Dopamine D2 Receptor AntagonistsProducts: FLUANXOL DEPOT 20MG/ML IM ENJ. SOLUSYON, 1 ADET
  10. Drug

    Tranexamic acid

    go.drugbank.com/drugs/DB00302
    ApprovedInvestigational

    [L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858] … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.

    Products: ACIDO TRANEXAMICO EG, TRANSAMINE 50 MG/ML IV ENJ COZELTI, 5 ML